17.64
+1.16(+7.04%)
Currency In USD
| Previous Close | 16.48 |
| Open | 16.64 |
| Day High | 17.81 |
| Day Low | 16.6 |
| 52-Week High | 19.17 |
| 52-Week Low | 3.5 |
| Volume | 434,684 |
| Average Volume | 1.14M |
| Market Cap | 1.15B |
| PE | 55.13 |
| EPS | 0.32 |
| Moving Average 50 Days | 14.1 |
| Moving Average 200 Days | 7.43 |
| Change | 1.16 |
If you invested $1000 in Monte Rosa Therapeutics, Inc. (GLUE) since IPO date, it would be worth $832.86 as of December 25, 2025 at a share price of $17.64. Whereas If you bought $1000 worth of Monte Rosa Therapeutics, Inc. (GLUE) shares 3 years ago, it would be worth $2,597.94 as of December 25, 2025 at a share price of $17.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
GlobeNewswire Inc.
Dec 16, 2025 12:00 PM GMT
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, including 2 patients with RECIST responses and 2 with
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
GlobeNewswire Inc.
Dec 15, 2025 9:01 PM GMT
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-ba
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
GlobeNewswire Inc.
Nov 08, 2025 4:30 PM GMT
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis Initial data from a Phase 1 study of